Nasdaq · CIK 0001683553
SPRB SPRUCE BIOSCIENCES, INC.
Insider trading from SEC Form 4. Last filing Jul 29, 2026. Close $44.05 on Oct 9, 2026, +6% from the 52-week low and -75% from the high.
In brief
SPRUCE BIOSCIENCES, INC. (SPRB) has 40 SEC Form 4 filings on file from 11 insiders, the latest filed on Jul 29, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
4 open-market trades have been scored at SPRB. The newest: Parkman Healthcare Partners LLC (10% owner) bought $4,585 of stock on Oct 6, 2025, filed Oct 15, 2025, scored 13 (weak). The largest of the 4 shown: Parkman Healthcare Partners LLC (10% owner) sold $4,920 on Oct 6, 2025, scored 17 (weak).
2 Form 144 notices of planned sales are on file, the latest filed Mar 18, 2024.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at SPRUCE BIOSCIENCES, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 13Weak | Parkman Healthcare Partners LLC owner buy | $4,585 256 shares | +24% | - | |
| 17Weak | Parkman Healthcare Partners LLC owner sell | $4,920 257 shares | -20% | - | |
| 13Weak | Parkman Healthcare Partners LLC owner buy | $4,585 256 shares | +24% | - | |
| 17Weak | Parkman Healthcare Partners LLC owner sell | $4,920 257 shares | -20% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 18, 2024 | Novo Holdings A/S 10% Stockholder | 4,810,020 11.69% of outstanding | $3.9M | Mar 18, 2024 | $1.7M |
| Mar 14, 2024 | Novo Holdings A/S 10% Stockholder | 1,912,316 4.66% of outstanding | $9.5M | Mar 14, 2024 | none |
Transactions
The newest 50 of 152 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Adrian W Quartel Chief Medical Officer | AGrant or award Restricted Stock Unitsderivative | +13,000 | $0.00 | $0 | 13,000 | Jul 29, 2026 |
| Jun 30, 2026 | Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER | AGrant or award Common Stock | +266 | $4.53 | $1,205 | 19,270 | Jul 9, 2026 |
| May 21, 2026 | Keli Walbert director | AGrant or award Stock Option (Right to Buy)derivative | +1,700 | $0.00 | $0 | 1,700 | May 26, 2026 |
| May 21, 2026 | Daniel K Spiegelman director | AGrant or award Stock Option (Right to Buy)derivative | +1,700 | $0.00 | $0 | 1,700 | May 26, 2026 |
| May 21, 2026 | Camilla Simpson V director | AGrant or award Stock Option (Right to Buy)derivative | +1,700 | $0.00 | $0 | 1,700 | May 26, 2026 |
| May 21, 2026 | Michael G Grey Executive Chairman | AGrant or award Stock Option (Right to Buy)derivative | +1,700 | $0.00 | $0 | 1,700 | May 26, 2026 |
| May 21, 2026 | Percival Barretto-Ko director | AGrant or award Stock Option (Right to Buy)derivative | +1,700 | $0.00 | $0 | 1,700 | May 26, 2026 |
| Mar 9, 2026 | Corwin Dale Hooks Chief Commercial Officer | AGrant or award Restricted Stock Unitsderivative | +11,000 | $0.00 | $0 | 11,000 | Mar 9, 2026 |
| Dec 11, 2025 | Douglas Kirk Ways Interim Chief Medical Officer | MOption exercise Common Stock | +1,250 | $0.00 | $0 | 1,250 | Jan 21, 2026 |
| Dec 11, 2025 | Douglas Kirk Ways Interim Chief Medical Officer | AGrant or award Restricted Stock Unitsderivative | +5,000 | $0.00 | $0 | 5,000 | Jan 21, 2026 |
| Dec 11, 2025 | Douglas Kirk Ways Interim Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -1,250 | $0.00 | $0 | 3,750 | Jan 21, 2026 |
| Dec 11, 2025 | Douglas Kirk Ways Interim Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +266 | - | - | 266 | Jan 21, 2026 |
| Dec 11, 2025 | Douglas Kirk Ways Interim Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -266 | - | - | 0 | Jan 21, 2026 |
| Dec 11, 2025 | Douglas Kirk Ways Interim Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +400 | - | - | 400 | Jan 21, 2026 |
| Dec 11, 2025 | Douglas Kirk Ways Interim Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -400 | - | - | 0 | Jan 21, 2026 |
| Dec 31, 2025 | Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER | AGrant or award Common Stock | +4,690 | $4.53 | $21k | 19,004 | Jan 5, 2026 |
| Dec 15, 2025 | Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +1,480 | $0.00 | $0 | 14,478 | Dec 17, 2025 |
| Dec 15, 2025 | Samir M. Gharib PRESIDENT AND CFO | MOption exercise Common Stock | +496 | $0.00 | $0 | 8,112 | Dec 17, 2025 |
| Dec 15, 2025 | Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER | FTax withholding Common Stock | -752 | $80.67 | $61k | 13,726 | Dec 17, 2025 |
| Dec 15, 2025 | Samir M. Gharib PRESIDENT AND CFO | FTax withholding Common Stock | -178 | $80.67 | $14k | 7,934 | Dec 17, 2025 |
| Dec 15, 2025 | Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +1,196 | $0.00 | $0 | 14,922 | Dec 17, 2025 |
| Dec 15, 2025 | Samir M. Gharib PRESIDENT AND CFO | MOption exercise Common Stock | +513 | $0.00 | $0 | 8,447 | Dec 17, 2025 |
| Dec 15, 2025 | Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER | FTax withholding Common Stock | -608 | $80.67 | $49k | 14,314 | Dec 17, 2025 |
| Dec 15, 2025 | Samir M. Gharib PRESIDENT AND CFO | FTax withholding Common Stock | -184 | $80.67 | $15k | 8,263 | Dec 17, 2025 |
| Dec 11, 2025 | Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER | AGrant or award Employee Stock Option (right to buy)derivative | +1,666 | - | - | 1,666 | Dec 17, 2025 |
| Dec 15, 2025 | Samir M. Gharib PRESIDENT AND CFO | MOption exercise Restricted Stock Unitsderivative | -496 | $0.00 | $0 | 497 | Dec 17, 2025 |
| Dec 11, 2025 | Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER | DDisposition to issuer Employee Stock Option (right to buy)derivative | -1,666 | - | - | 0 | Dec 17, 2025 |
| Dec 15, 2025 | Samir M. Gharib PRESIDENT AND CFO | MOption exercise Restricted Stock Unitsderivative | -513 | $0.00 | $0 | 1,027 | Dec 17, 2025 |
| Dec 15, 2025 | Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitsderivative | -1,480 | $0.00 | $0 | 1,480 | Dec 17, 2025 |
| Dec 15, 2025 | Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER | MOption exercise Restricted Stock Unitsderivative | -1,196 | $0.00 | $0 | 2,392 | Dec 17, 2025 |
| Dec 11, 2025 | Camilla Simpson V director | AGrant or award Stock Option (Right to Buy)derivative | +173 | - | - | 173 | Dec 15, 2025 |
| Dec 11, 2025 | Samir M. Gharib PRESIDENT AND CFO | AGrant or award Stock Option (Right to Buy)derivative | +1,579 | - | - | 1,579 | Dec 15, 2025 |
| Dec 11, 2025 | Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER | AGrant or award Employee Stock Option (right to buy)derivative | +10,000 | - | - | 10,000 | Dec 15, 2025 |
| Dec 11, 2025 | Percival Barretto-Ko director | AGrant or award Stock Option (Right to Buy)derivative | +800 | - | - | 800 | Dec 15, 2025 |
| Dec 11, 2025 | Daniel K Spiegelman director | AGrant or award Stock Option (Right to Buy)derivative | +458 | - | - | 458 | Dec 15, 2025 |
| Dec 11, 2025 | Michael G Grey Executive Chairman | AGrant or award Stock Option (Right to Buy)derivative | +387 | - | - | 387 | Dec 15, 2025 |
| Dec 11, 2025 | Keli Walbert director | AGrant or award Stock Option (Right to Buy)derivative | +3,400 | $0.00 | $0 | 3,400 | Dec 15, 2025 |
| Dec 11, 2025 | Michael G Grey Executive Chairman | DDisposition to issuer Stock Option (Right to Buy)derivative | -387 | - | - | 0 | Dec 15, 2025 |
| Dec 11, 2025 | Camilla Simpson V director | DDisposition to issuer Stock Option (Right to Buy)derivative | -173 | - | - | 0 | Dec 15, 2025 |
| Dec 11, 2025 | Samir M. Gharib PRESIDENT AND CFO | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,579 | - | - | 0 | Dec 15, 2025 |
| Dec 11, 2025 | Percival Barretto-Ko director | DDisposition to issuer Stock Option (Right to Buy)derivative | -800 | - | - | 0 | Dec 15, 2025 |
| Dec 11, 2025 | Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER | DDisposition to issuer Employee Stock Option (right to buy)derivative | -10,000 | - | - | 0 | Dec 15, 2025 |
| Dec 11, 2025 | Daniel K Spiegelman director | DDisposition to issuer Stock Option (Right to Buy)derivative | -458 | - | - | 0 | Dec 15, 2025 |
| Dec 11, 2025 | Camilla Simpson V director | AGrant or award Stock Option (Right to Buy)derivative | +309 | - | - | 309 | Dec 15, 2025 |
| Dec 11, 2025 | Samir M. Gharib PRESIDENT AND CFO | AGrant or award Stock Option (Right to Buy)derivative | +953 | - | - | 953 | Dec 15, 2025 |
| Dec 11, 2025 | Daniel K Spiegelman director | AGrant or award Stock Option (right to buy)derivative | +88 | - | - | 88 | Dec 15, 2025 |
| Dec 11, 2025 | Michael G Grey Executive Chairman | AGrant or award Stock Option (Right to Buy)derivative | +1,255 | - | - | 1,255 | Dec 15, 2025 |
| Dec 11, 2025 | Camilla Simpson V director | DDisposition to issuer Stock Option (Right to Buy)derivative | -309 | - | - | 0 | Dec 15, 2025 |
| Dec 11, 2025 | Samir M. Gharib PRESIDENT AND CFO | DDisposition to issuer Stock Option (Right to Buy)derivative | -953 | - | - | 0 | Dec 15, 2025 |
| Dec 11, 2025 | Michael G Grey Executive Chairman | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,255 | - | - | 0 | Dec 15, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Percival Barretto-Kodirector
- Michael G GreyExecutive Chairman
- Samir M. GharibPresident & CFO
- Corwin Dale HooksChief Commercial Officer
- Parkman Healthcare Partners LLCowner
- Adrian W QuartelChief Medical Officer
- Camilla Simpson Vdirector
- Daniel K Spiegelmandirector
- Javier B. SzwarcbergChief Executive Officer
- Keli Walbertdirector
- Douglas Kirk WaysInterim Chief Medical Officer
Questions about SPRB
Answered from the filings on this page, as of the latest one.
Are insiders buying SPRB?
No. In the last 90 days no insider at SPRUCE BIOSCIENCES, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade SPRB on the open market?
Parkman Healthcare Partners LLC (10% owner) bought $4,585 of SPRB on Oct 6, 2025 and filed the Form 4 on Oct 15, 2025. InsiderTell scored 13 (weak).
How many insiders file Form 4 at SPRUCE BIOSCIENCES, INC.?
11 people have filed a Form 4 at SPRUCE BIOSCIENCES, INC., among them Percival Barretto-Ko (director), Michael G Grey (Executive Chairman), Samir M. Gharib (President & CFO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.